Treatment options in hormone resistant prostate cancer

Ann Oncol. 2002:13 Suppl 4:95-102. doi: 10.1093/annonc/mdf645.

Authors

P H M De Mulder¹, J A Schalken, C N Sternberg

Affiliation

¹ Department of Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

PMID: 12401673
DOI: 10.1093/annonc/mdf645

No abstract available

Publication types

Review

MeSH terms

Aged
Androgen Antagonists / administration & dosage
Androgen Antagonists / adverse effects
Angiogenesis Inhibitors / administration & dosage*
Antineoplastic Agents, Hormonal / administration & dosage*
Antineoplastic Agents, Hormonal / adverse effects
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Drug Resistance, Neoplasm*
Humans
Immunotherapy / methods*
Male
Middle Aged
Neoplasms, Hormone-Dependent / diagnosis
Neoplasms, Hormone-Dependent / mortality
Neoplasms, Hormone-Dependent / therapy*
Prognosis
Prostatic Neoplasms / diagnosis
Prostatic Neoplasms / mortality
Prostatic Neoplasms / therapy*
Randomized Controlled Trials as Topic
Receptors, Growth Factor / antagonists & inhibitors*
Survival Rate
Treatment Outcome

Substances

Androgen Antagonists
Angiogenesis Inhibitors
Antineoplastic Agents, Hormonal
Receptors, Growth Factor